European journal of pain : EJP
-
Randomized Controlled Trial
The role of excess subcutaneous fat in pain and sensory sensitivity in obesity.
Previous studies suggest pain sensitivity may be decreased in obesity, but it is unknown whether this is a global or a site-specific phenomenon related to the amount of excess fat. ⋯ Obese participants are less sensitive than non-obese individuals, but only on areas with excess subcutaneous fat.
-
Thyroid hormones (THs) play a crucial role in the development of several organic systems. An adequate support of maternal THs may be required to ensure a normal nociceptive function of offspring into adulthood. We investigated the impact of experimental gestational hypothyroidism (EGH) on nociceptive threshold and motor performance in the offspring at different post-natal days (PND) in both male and female rats. ⋯ EGH promotes hypersensitivity to noxious thermal but not mechanical stimulus. Moreover, motor force is similarly reduced in male and female OMTDs, whereas motor performance is reduced only in mature male OMTD, suggesting the presence of a protective factor in females.
-
This study aimed (1) to assess the validity of a virtual reality (VR) intervention designed specifically to gain control over pain, (2) to test whether the association between the virtual environment and pain can be potentiated using a differential conditioning procedure, and (3) to examine the effects of this VR intervention in a cold pressor experiment. ⋯ These results provide preliminary support for the use of our VR intervention to gain control over pain.
-
l-Kynurenine has antinociceptive effects in acute and inflammatory pain. This study determined the effect of l-kynurenine and its metabolite (kynurenic acid) on rats subjected to neuropathic pain. ⋯ l-Kynurenine produces its antiallodynic effect in the central nervous system through kynurenic acid. This effect may result from blockade of N-methyl-d-aspartate receptors. KAT II is expressed in dorsal root ganglion and dorsal spinal cord. Combined l-kynurenine and probenecid therapy has the potential to reduce neuropathic pain in humans.